申请人:Univerza Edvarda Kardelja v Ljubljana
公开号:US05231216A1
公开(公告)日:1993-07-27
There are described novel trans-2-acylaminocyclohexyloxyacyldipeptides of formula I ##STR1## wherein R.sub.1 represents --CO--R.sub.6, --SO.sub.2 --R.sub.7 or ##STR2## R.sub.6 is C.sub.1 -C.sub.18 alkyl or C.sub.1 -C.sub.18 alkoxy, R.sub.7 is C.sub.1 -C.sub.18 alkyl or an optionally substituted phenyl group, Y is .dbd.O, .dbd.S or .dbd.NH; R.sub.2 =R.sub.3 and represent --H or C.sub.1 -C.sub.12 alkyl, R.sub.4 represents --OR.sub.8 or --NHR.sub.9, R.sub.8 is --H, C.sub.1 -C.sub.8 alkyl or benzyl, R.sub.9 is --H, a straight or branched chain C.sub.1 -C.sub.18 alkyl group or benzyl group; R.sub.5 represents --OR.sub.9 or --NHR.sub.9, and novel (1R,2R)- and (1S,2S)-trans-2-acylaminocyclohexyloxyacetyldipeptides of the formulas Ia and Ib ##STR3## wherein R.sub.1 is --CO--R.sub.6, R.sub.6 is C.sub.1 -C.sub.18 alkyl, R.sub.2 is --H, R.sub.3 is --H or C.sub.1 -C.sub.12 alkyl, R.sub.4 is --OR.sub.8 or --NHR.sub.9, R.sub.8 is --H, C.sub.1 -C.sub.8 alkyl or benzyl, R.sub.9 is --H, C.sub.1 -C.sub.18 alkyl or benzyl, R.sub.5 is --OR.sub.9 or --NHR.sub.9 Compounds of formula I, Ia and Ib and the pharmaceutically acceptable alkali salts thereof show immunomodulatory and antitumour activities and can be used in the preparation of medicaments.
描述了一种新型的trans-2-acylaminocyclohexyloxyacyldipeptides,其化学式为I ##STR1## 其中R.sub.1代表--CO--R.sub.6,--SO.sub.2 --R.sub.7或##STR2## R.sub.6是C.sub.1 -C.sub.18烷基或C.sub.1 -C.sub.18烷氧基,R.sub.7是C.sub.1 -C.sub.18烷基或一个可选择替代的苯基,Y是.dbd.O,.dbd.S或.dbd.NH;R.sub.2 =R.sub.3代表--H或C.sub.1 -C.sub.12烷基,R.sub.4代表--OR.sub.8或--NHR.sub.9,R.sub.8是--H,C.sub.1 -C.sub.8烷基或苄基,R.sub.9是--H,一种直链或支链C.sub.1 -C.sub.18烷基或苄基;R.sub.5代表--OR.sub.9或--NHR.sub.9,以及新型的(1R,2R)-和(1S,2S)-trans-2-acylaminocyclohexyloxyacetyldipeptides,其化学式为Ia和Ib ##STR3## 其中R.sub.1是--CO--R.sub.6,R.sub.6是C.sub.1 -C.sub.18烷基,R.sub.2是--H,R.sub.3是--H或C.sub.1 -C.sub.12烷基,R.sub.4是--OR.sub.8或--NHR.sub.9,R.sub.8是--H,C.sub.1 -C.sub.8烷基或苄基,R.sub.9是--H,C.sub.1 -C.sub.18烷基或苄基,R.sub.5是--OR.sub.9或--NHR.sub.9,化合物I、Ia和Ib及其药学上可接受的碱盐显示出免疫调节和抗肿瘤活性,可用于药物的制备。